NCBP1: A Potential Drug Target for Cell Signaling and Gene Regulation

Target Name: NCBP1

NCBI ID: G4686

NCBP1

NCBP1: A Potential Drug Target for Cell Signaling and Gene Regulation

Nuclear cap binding protein subunit 1 (NCBP1) is a protein that is expressed in various tissues and cells in the human body. It plays a critical role in the regulation of nuclear cap, which is a protein that is found in the nucleus of cells. The function of NCBP1 is to bind to the nuclear cap and help to regulate the movement of RNA into the nucleus.

NCBP1 is a 24-kDa protein that is expressed in various tissues and cells in the human body. It is highly conserved, with a calculated amino acid sequence of 21.1% identity across different species, including humans, mouse, and rat. NCBP1 is primarily expressed in the brain, heart, and testes, and is also found in other tissues and cells, such as muscle, liver, and kidney.

NCBP1 is a key protein that is involved in the regulation of nuclear cap. Nuclear cap is a protein that is found in the nucleus of cells and plays a critical role in the regulation of gene expression. It is composed of several subunits, including the NCBP1 subunit. The NCBP1 subunit is responsible for binding to the nuclear cap and helping to regulate the movement of RNA into the nucleus.

NCBP1 is a nucleosome-remodeling protein, which means that it helps to maintain the integrity of the nuclear genome by regulating the movement of DNA and RNA into the nucleus. It does this by binding to the nuclear cap, which is a protein that is found in the nucleus of cells. The binding of NCBP1 to the nuclear cap allows it to regulate the movement of RNA into the nucleus, where it can interact with DNA and RNA to carry out various genetic instructions.

NCBP1 is also involved in the regulation of cell signaling pathways. It plays a critical role in the regulation of mitochondrial function, and is also involved in the regulation of cellular signaling pathways that are involved in cell growth, differentiation, and survival.

NCBP1 is a potential drug target and may be a biomarker for various diseases. Its involvement in the regulation of nuclear cap and its role in the regulation of cellular signaling pathways make it an attractive target for drug development. There are several studies that have identified potential drug candidates that target NCBP1, and further research is being conducted to determine the efficacy of these compounds in treating various diseases.

In conclusion, NCBP1 is a protein that is expressed in various tissues and cells in the human body. It plays a critical role in the regulation of nuclear cap and its function is highly conserved across different species. The potential drug target and biomarker status of NCBP1 make it an attractive target for further research and development of new treatments.

Protein Name: Nuclear Cap Binding Protein Subunit 1

Functions: Component of the cap-binding complex (CBC), which binds cotranscriptionally to the 5'-cap of pre-mRNAs and is involved in various processes such as pre-mRNA splicing, translation regulation, nonsense-mediated mRNA decay, RNA-mediated gene silencing (RNAi) by microRNAs (miRNAs) and mRNA export. The CBC complex is involved in mRNA export from the nucleus via its interaction with ALYREF/THOC4/ALY, leading to the recruitment of the mRNA export machinery to the 5'-end of mRNA and to mRNA export in a 5' to 3' direction through the nuclear pore. The CBC complex is also involved in mediating U snRNA and intronless mRNAs export from the nucleus. The CBC complex is essential for a pioneer round of mRNA translation, before steady state translation when the CBC complex is replaced by cytoplasmic cap-binding protein eIF4E. The pioneer round of mRNA translation mediated by the CBC complex plays a central role in nonsense-mediated mRNA decay (NMD), NMD only taking place in mRNAs bound to the CBC complex, but not on eIF4E-bound mRNAs. The CBC complex enhances NMD in mRNAs containing at least one exon-junction complex (EJC) via its interaction with UPF1, promoting the interaction between UPF1 and UPF2. The CBC complex is also involved in 'failsafe' NMD, which is independent of the EJC complex, while it does not participate in Staufen-mediated mRNA decay (SMD). During cell proliferation, the CBC complex is also involved in microRNAs (miRNAs) biogenesis via its interaction with SRRT/ARS2 and is required for miRNA-mediated RNA interference. The CBC complex also acts as a negative regulator of PARN, thereby acting as an inhibitor of mRNA deadenylation. In the CBC complex, NCBP1/CBP80 does not bind directly capped RNAs (m7GpppG-capped RNA) but is required to stabilize the movement of the N-terminal loop of NCBP2/CBP20 and lock the CBC into a high affinity cap-binding state with the cap structure. Associates with NCBP3 to form an alternative cap-binding complex (CBC) which plays a key role in mRNA export and is particularly important in cellular stress situations such as virus infections. The conventional CBC with NCBP2 binds both small nuclear RNA (snRNA) and messenger (mRNA) and is involved in their export from the nucleus whereas the alternative CBC with NCBP3 does not bind snRNA and associates only with mRNA thereby playing a role only in mRNA export. NCBP1/CBP80 is required for cell growth and viability (PubMed:26382858)

The "NCBP1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NCBP1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets